Helius Medical Technologies Announces Receipt Of Remainder Of A&B Funding, Changes To Board Of Directors, And Extension Of CRADA Agreement Through December 2017

NEWTOWN, Pa.--(BUSINESS WIRE)--Helius Medical Technologies, Inc. (CSE:HSM; OTCQB:HSDT) (“Helius”, or the “Company”), a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, today announced that the Company has elected to draw down on the remaining USD $5 million credit facility from A&B (HK) Company Limited (“A&B”), appointed two new members to its Board of Directors and obtained an extension to its Cooperative Research and Development Agreement (“CRADA”) with the US Army Medical Research and Material Command (“USAMRMC”).

Back to news